Breast cancer resistance protein (BCRP) and multidrug resistance protein 4 (MRP4) are 18 involved in uric acid excretion in humans and mice. Despite evidence suggesting that chicken 19 renal proximal tubular epithelial cells participate in uric acid secretion, the roles of BCRP and 20 MRP4 in chickens remain unclear. This study evaluated the relationship between chicken 21 BCRP and MRP4 expression and renal function in the liver, kidneys, and intestines. Sixty 22 20-day-old Isa brown laying hens were randomly divided into four groups: a control group 23 (NC) and groups provided with sulfonamide-treated drinking water (SD), a diet 24 supplemented with fishmeal (FM), and an intraperitoneal injection of uric acid (IU). Serum 25 uric acid, creatinine, and blood urea nitrogen (BUN) levels were significantly higher in the 26 SD and IU groups than in the NC group. BCRP and MRP4 levels in the SD and IU groups 27 were significantly increased in the kidneys and ileum and decreased in the liver. In the FM 28 group, BCRP and MRP4 were significantly increased in the kidneys and slightly increased in 29 the ileum. These results demonstrate that chicken BCRP and MRP4 are involved in renal and 30 intestinal uric acid excretion. When renal function is impaired, serum uric acid increased and 31 BCRP and MRP4 in the liver, kidneys, and ileum exhibit compensatory increases; when renal 32 function is normal, serum uric acid changes have no effect on ileum BCRP and MRP4 33 expression. Therefore, this study may provide the references to the uric acid regulation in 34 human. 35 
Introduction
Uric acid (urate) is the final product of purine metabolism. Although in some cases, dietary 40 [39], genetic [15, 24] , or disease-related [13] uric acid overproduction is the basis of 41 hyperuricemia, the main cause, in fact, of hyperuricemia is reduced uric acid excretion [23, 42 30]. In an analysis of uric acid metabolism in 65 patients with hyperuricemia, six (9.2%) 43 exhibited an overproduction phenotype, 52 (80.0%) exhibited an underexcretion phenotype, 44 and seven (10.8%) exhibited a mixed phenotype [23] . The kidney is the main organ 45 responsible for uric acid excretion, accounting for approximately two-thirds of the total uric 46 excretion in the body; the remaining one-third mainly involves the intestines [16] . This 47 process involves several uric acid transporters; breast cancer resistance protein (BCRP; 48 ABCG2) and multidrug resistance protein 4 (MRP4; ABCC4) are the major proteins involved 49 in uric acid excretion and expression in the human liver, kidneys, and intestines [12, 18, 25, 50 31]. BCRP is a high-capacity uric acid transporter that physiologically mediates renal and 51 extra-renal (intestinal) uric acid excretion; its dysfunction leads to hyperuricemia [19] . 52 Extensive data indicates that BCRP plays an important role in intestinal uric acid excretion in 53 mice and humans [11] . Renal uric acid excretion is significantly reduced after nephrectomy in 54 mice, while serum uric acid does not change and ileum BCRP expression is significantly 55 increased [37] . Therefore, alterations in intestinal BCRP may serve as a compensatory 56 mechanism. When renal uric acid excretion is reduced, intestinal uric acid excretion is 57 increased to maintain the uric balance. 58 Many studies have examined the functions of human, rat, and mouse BCRP in the kidneys 59 and intestines; however, relatively few studies have evaluated MRP4. Similar to BCRP, 60 MRP4 is a uric acid unidirectional efflux pump with multiple allosteric substrate binding sites, 61 which is expressed in the apical membrane of human renal proximal tubules [32] . It is 62 responsible for uric acid excretion by transporting uric acid from tubular epithelial cells into 63 renal tubule lumens. MRP4 is also expressed in the basal membrane of human hepatocytes 64 and is involved in the transport of uric acid in the liver [27] . In HEK293 cells, MRP4 can 65 transport uric acid concurrently with cAMP or cGMP and uric acid excretion increases with 66 the overexpression of MRP4 [31] . 67 Uricase in the mouse liver can convert uric acid into allantoin; however, human and 68 chicken livers lack uricase [35] . Accordingly, uric acid metabolism in humans occurs via a 69 different mechanism than in mice. Therefore, the chicken may constitute a more useful model 70 than mice for studying human uric acid transporters. In vitro studies have demonstrated the 71 presence of active urate secretion in chicken renal proximal tubular epithelial cells (cPTCs) 72 and this may be related to multiple uric acid transporters [8] . Subsequently, Bataille et al. [2] 73 showed that BCRP and MRP4 are expressed in cPTCs and that uric acid secretion is reduced 74 by 60-70% in response to a 75% reduction in chicken Mrp4 expression by short hairpin RNA 75 interference. The net transepithelial transport of uric acid decreases when BCRP is knocked 76 down [3], though the change is not significant, indicating that MRP4 is the main route for 77 urate secretion in chicken proximal tubules. However, the roles of BCRP and MRP4 in 78 chicken uric acid excretion remain unclear. Therefore, the aim of this study was to investigate 79 the relationship between serum uric acid levels and BCRP and MRP4 levels in the liver, 80 kidneys, and intestines and to evaluate kidney and extrarenal uric acid excretion in chickens. 81 These findings may lay the foundation for the treatment and prevention of hyperuricemia. 
Results

142
Renal function 143 As shown in Table 2 , compared with the control group, serum uric acid levels were higher 144 (p = 0.01) and creatinine and BUN levels were significantly higher (p < 0.01) in the 145 sulfonamide-treated drinking water (SD) group. Serum uric acid, creatinine, and BUN levels 146 were significantly higher in the intraperitoneal injection of uric acid (IU) group than in the 147 control group (p < 0.01); however, there was no significant difference between the diet 148 supplemented with fishmeal (FM) group and the control group. 149 150 Real-time quantitative PCR and western blotting were used to detect the distributions of 151 BCRP and MRP4 in the liver, kidneys, jejunum, and ileum of normal chickens (Fig. 1) . The 152 results showed that chicken BCRP ( Fig. 1A) was highly expressed in the jejunum and ileum 153 (p < 0.01), lowly expressed in the liver, and minimally expressed in the kidneys (p < 0.01).
BCRP and MRP4 mRNA and protein expression in normal chickens
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MRP4 expression was similar to that of BCRP ( Fig. 1B) ; its expression levels in the liver and 155 kidneys were lower than in the jejunum and ileum (p < 0.01), but did not differ significantly 156 between the liver and kidneys. In addition, relative expression analyses showed that BCRP 157 and MRP4 were mainly expressed in the jejunum and ileum. BCRP levels were higher than 158 MRP4 levels in the jejunum, ileum, and liver and BCRP and MRP4 levels did not differ 159 significantly in the kidneys (Fig. 1C ). 160 Immunohistochemical staining showed that BCRP and MRP4 were expressed in the liver 161 cells, renal apical membrane, intestinal smooth muscle, and intestinal villi ( Fig. 2 and Fig. 3 ). 162 Moreover, MRP4 levels in these four tissues were lower than BCRP levels. 163 164 BCRP and MRP4 mRNA levels in the liver, kidneys, jejunum, and ileum of chickens in 165 each treatment group were evaluated by qPCR. BCRP and MRP4 levels showed similar 166 trends. As shown in Fig. 4 , compared with the control group, BCRP and MRP4 levels were 167 significantly higher (p < 0.05, p < 0.01) in the ileum and slightly higher in the kidneys of the 168 SD group. BCRP and MRP4 levels were significantly increased in the kidneys and ileum of 169 the IU group. Additionally, in the SD and IU groups, BCRP and MRP4 expression levels 170 were significantly decreased in the liver (p < 0.05, p < 0.05). In the FM group, BCRP and 171 MRP4 expression levels in the kidneys were significantly increased (p < 0.05, p < 0.05), the 172 levels in the ileum were slightly increased, and there was no obvious difference in the liver. 173 Moreover, BCRP and MRP4 expression levels in the jejunum of the three experimental 174 groups showed a decreasing trend, though the difference was not significant. 175 Western blotting results showed that BCRP and MRP4 expression levels in the liver, 176 kidneys, jejunum, and ileum of each group were consistent with the mRNA expression levels 177 ( Fig. 5 ). In the SD group, BCRP and MRP4 protein levels were slightly increased in the 178 kidneys and significantly increased in the ileum (p < 0.05, p < 0.01). In the IU group, BCRP 179 and MRP4 protein levels were significantly increased in the kidneys and ileum. In the SD and 180 IU groups, BCRP and MRP4 levels were decreased in the liver. In the FM group, BCRP and 181 MRP4 protein levels were significantly increased in the kidneys (p < 0.01, p < 0.05) and 182 slightly increased in the ileum, while there was no significant difference in the liver levels 183 compared to the control group. BCRP and MRP4 protein levels in the jejunum of the three 184 experimental groups did not differ significantly. 185 Finally, we used immunohistochemistry to evaluate BCRP and MRP4 protein expression 186 levels in the liver, kidneys, jejunum, and ileum in each treatment group. As shown in Fig 
BCRP and MRP4 expression in various treatment groups
